← Therapy pipeline
Investigational · Obesity development

MET233i

PF-08653945 · PF’3945 · Pfizer / Metsera

Long-acting amylin analogue with dual amylin/calcitonin activity.

amylin
Obesity stagePhase 2Updated as of November 2026
SponsorPfizer / Metsera
Targetsamylin
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.

02 / How it works

Mechanism at a glance

GLP-1GLP-1—
GIPGIP—
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 2Initiated
Milestone → next

Latest: Pfizer lists monotherapy in Phase 2 obesity development.

Next: Phase 2 dose and dosing-interval results.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies1 record

Phase 2b

SOLIS-1 · PF-08653945 monotherapy arms

Weight management / amylin monotherapy
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with overweight or obesity; the SOLIS-1 master trial includes PF-08653945 monotherapy and combination arms. This profile refers to the amylin-analogue component.